Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $18.00 for the company and are expecting that the company will post $0.10 EPS for the current quarter, according to Zacks. Zacks has also given Simulations Plus an industry rank of 163 out of 265 based on the ratings given to related companies.
A number of analysts have issued reports on SLP shares. Zacks Investment Research downgraded Simulations Plus from a “buy” rating to a “hold” rating in a report on Wednesday, September 20th. BidaskClub raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Thursday, October 5th.
Shares of Simulations Plus (NASDAQ SLP) remained flat at $$16.30 during midday trading on Thursday. The stock had a trading volume of 43,541 shares, compared to its average volume of 52,817. The company has a market capitalization of $281.88, a PE ratio of 46.57 and a beta of -0.76. Simulations Plus has a 1-year low of $9.45 and a 1-year high of $17.45.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Tuesday, November 14th. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.01. The company had revenue of $6.30 million during the quarter, compared to the consensus estimate of $5.01 million. Simulations Plus had a return on equity of 24.56% and a net margin of 23.78%. research analysts anticipate that Simulations Plus will post 0.39 EPS for the current fiscal year.
In other news, CEO Walter S. Woltosz sold 18,500 shares of the business’s stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $16.25, for a total value of $300,625.00. Following the completion of the sale, the chief executive officer now directly owns 5,502,416 shares of the company’s stock, valued at approximately $89,414,260. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 74,000 shares of company stock valued at $1,196,025 over the last three months. Company insiders own 33.45% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in Simulations Plus by 13.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,923 shares of the technology company’s stock valued at $110,000 after acquiring an additional 1,085 shares during the last quarter. OxFORD Asset Management LLP purchased a new stake in Simulations Plus during the 2nd quarter valued at approximately $126,000. Rhumbline Advisers purchased a new stake in Simulations Plus during the 2nd quarter valued at approximately $126,000. New York State Common Retirement Fund purchased a new stake in Simulations Plus during the 2nd quarter valued at approximately $143,000. Finally, Teachers Advisors LLC purchased a new stake in Simulations Plus during the 2nd quarter valued at approximately $239,000. 33.56% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Simulations Plus, Inc. (SLP) to Announce $0.10 EPS” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://ledgergazette.com/2018/01/14/brokerages-anticipate-simulations-plus-inc-slp-to-announce-0-10-eps.html.
About Simulations Plus
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.